Clinical Trial Update: Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study [Phase 2]

View source ↗

Summary

Phase 2 trial update on MTP-131 for primary mitochondrial disease reporting safety, tolerability, and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Disease

Drugs mentioned

• MTP-131 (elamipretide)

Snippet

Sponsor: Stealth BioTherapeutics Inc. | Conditions: Primary Mitochondrial Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-07-07